Nordic Nanovector

334 articles with Nordic Nanovector

• Safety Review Committee For Nordic Nanovector's Lymrit 37-01 Trial Recommends Dose Escalation To 20 MBq/kg With Betalutin

  11/4/2016

• Nordic Nanovector: Updated Results From Phase 1/2 Trial Of Betalutin In Non-Hodgkin Lymphoma To Be Presented At American Society of Hematology Annual Meeting In December

  11/3/2016

• Nordic Nanovector: Results From Preclinical Studies Of Betalutin In Combination With Rituximab In Non-Hodgkin Lymphoma Model To Be Presented At American Society of Hematology

  11/3/2016

• Nordic Nanovector And Heidelberg Pharma Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCs) Targeting Leukaemias

  10/26/2016

• Nordic Nanovector: Extraordinary General Meeting Held

  10/12/2016

• Nordic Nanovector Announces The Appointment Of Joanna Horobin, MD As Non-Executive Board Director

  10/12/2016

• Nordic Nanovector And LegoChem Biosciences Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCS) Targeting Leukemias

  10/10/2016

• Nordic Nanovector – Changes To The Board Of Directors And Notice Of Extraordinary General Meeting

  9/21/2016

• Nordic Nanovector – Notification Of Share Capital Increase

  9/13/2016

• Nordic Nanovector: Lilotomab Pre-Dosing Of NHL Patients Before Betalutin Therapy Lowers Hematological Toxicity With No Reduction In The Tumor Absorbed Radiation Dose

  9/6/2016

• Nordic Nanovector - Financial Calendar

  8/31/2016

• Nordic Nanovector — Results For Second Quarter And Half Year 2016

  8/24/2016

• Nordic Nanovector Completes Recruitment Of The First Cohorts Of Arm 3 And Arm 4 Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients

  8/18/2016

• Nordic Nanovector: Second Quarter And First Half 2016 Results Presentation And Webcast

  8/16/2016

• Nordic Nanovector: Second Quarter And First Half 2016 Results Presentation And Webcast

  8/16/2016

• Nordic Nanovector And Areva Med To Investigate Potential Of Lead-212 Conjugated Anti-Cd37 Antibody For Treating Leukaemias

  6/28/2016

• Nordic Nanovector: Pre-Dosing NHL Patients With HH1 Anti-CD37 Antibody Before Betalutin® Increases Its Pharmacokinetic Exposure And Reduces Its Haematological Toxicity

  6/10/2016

• BIO2016: Nordic Nanovector To Present At BIO International Convention On 7 June 2016

  6/3/2016

• Nordic Nanovector: Allotment Of Restricted Stock Unites (RSUs) To The Board Of Directors

  5/31/2016

• Nordic Nanovector Capital Markets Day 2016 To Highlight Strong Progress Towards Vision Of Becoming A Significant Player In Haematological Cancers

  5/31/2016